📰 Recursion Pharmaceuticals News
Page 49 - Recursion Pharmaceuticals News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Recursion Pharmaceuticals. Real-time updates on events, politics, business and more.
October 11, 2021
In this article, we discuss the top 10 picks in Harvard Universitys stock portfolio.
October 8, 2021
/PRNewswire/ -- DelveInsights Huntingtons Disease Market Insights report provides a thorough understanding of current treatment practices, emerging drugs,...
October 8, 2021
The untapped market of Huntington's Disease is anticipated to expand primarily because of the introduction of novel emerging therapies, rising prevalence and elderly population, increased R&D
October 8, 2021
In this article, we discuss Cathie Wood stock portfolio: 10 newest stock picks this year.
October 8, 2021
/PRNewswire/ -- DelveInsights Huntingtons Disease Market Insights report provides a thorough understanding of current treatment practices, emerging drugs,...
August 18, 2021
Fifteen years ago, Aydin Senkut, a former Google exec, was an outsider in venture circles that didn’t take seriously his ambitions to become a top VC. Now, his firm, Felicis Ventures, is announcing $900 million in capital commitments across two new funds — a $600 million early-stage fund and a $300 million opportunities-type fund to […]
August 13, 2021
SALT LAKE CITY (AP) _ Recursion Pharmaceuticals Inc. (RXRX) on Friday reported a loss of...
July 3, 2021
Deseret News Share this story Lawrie Allred, HTS engineer, hands a cell plate to a co-worker while seeding cells at Recursion Pharmaceuticals at The Gateway in Salt Lake City on Oct. 30, 2018. This week, the company announced it will double the footprint of its flagship research and office facility, signing a lease on an additional 100,000 square feet of space at The Gateway. Kristin Murphy, Deseret News Utah biotech startup Recursion Pharmaceuticals is upending the realm of clinical-stage drug...
July 3, 2021
SALT LAKE CITY — Utah biotech startup Recursion Pharmaceuticals is upending the realm of clinical-stage drug research, melding robot-driven automation with digital artificial intelligence on a mission to revolutionize how new medications are developed to battle some of the rarest and most challenging of human medical conditions. And the company has been on an absolute tear in the last year, raising over $500 million via a public stock offering in April, expanding its footprint with a new rese...